Form 4: Cara Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Posner, CEO of Cara Therapeutics, sold 4,149 shares of common stock at $0.35 per share to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On August 1, 2024, Christopher Posner, the President and CEO of Cara Therapeutics, Inc., sold 4,149 shares of the company's common stock.
- The sale was executed at a price of $0.35 per share.
- The transaction was conducted to cover tax withholding obligations triggered by the vesting of restricted stock units.
- Following the transaction, Posner directly owns 172,436 shares of Cara Therapeutics common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as the filing relates to a routine transaction for tax purposes and doesn't indicate a significant change in the company's outlook.
Industry Context
This is a routine Form 4 filing, reflecting an insider transaction related to tax obligations. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 11/02/2022 | Date of adoption of 'sell to cover' arrangement by the Reporting Person in accordance with Rule 10b5-1. |
| 08/01/2024 | Date of transaction: Sale of 4,149 shares of Common Stock. |
| 08/02/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.